Synthetic data is moving from “more training rows” to “safer sharing and valid conclusions.” Today’s set spans rare-disease evidence mapping, model/tooling tutorials, statistical guarantees, and two clinical generation case studies.
Data Augmentation and Synthetic Data Generation in Rare Disease Research: A Scoping Review
A PubMed Central scoping review maps how data augmentation and synthetic data generation are being used in rare disease research. The authors screened 2,864 candidate studies to catalog techniques, purposes, and recurring methodological challenges. The review highlights that synthetic approaches are often used to counter extreme data scarcity, including reports of dataset expansion up to 10× or more, while repeatedly flagging validation and biological plausibility as the hard part.
- For ML leads, the takeaway is less “generate more” and more “prove it’s plausible”: plan validation beyond holdout accuracy (e.g., clinician review, distributional checks, and task-specific clinical constraints).
- For founders, the market gap is tooling that standardizes rare-disease synthetic data QA, not just generation.
- For compliance teams, the review’s emphasis on rigor supports governance requirements: document purpose, method, and limitations before downstream use.
Generative Models for Synthetic Data: Transforming Data Mining in the GenAI Era
This arXiv tutorial surveys synthetic data generation with generative models, including LLMs, diffusion models, and GANs. It focuses on methodologies, frameworks, and evaluation strategies rather than proposing a single new model. For practitioners, it’s a compact map of the design space: what to generate, how to condition it, and how to evaluate utility and risk.
- Useful as an internal “shared vocabulary” for teams comparing LLM-based tabular synthesis vs. diffusion for images vs. GAN baselines.
- Evaluation is positioned as first-class work: expect to budget time for utility metrics, privacy checks, and failure-mode analysis.
Valid Inference with Imperfect Synthetic Data
Another arXiv paper tackles a governance pain point: how to make statistically valid conclusions when synthetic data (generated by LLMs) is imperfect, especially in limited-data regimes. The authors introduce a new estimator based on generalized method of moments for combining synthetic and real data. The intended outcome is theoretical backing for inference, with applications noted in computational social science and human subjects research.
- If your org mixes real + synthetic for analysis, this is a step toward defensible inference—not just model training.
- For review boards and auditors, “theoretical guarantees” can translate into clearer acceptance criteria for when synthetic augmentation is permissible.
- For data scientists, it suggests a workflow shift: treat synthetic data as a biased measurement process that needs correction, not a drop-in replacement.
Using generative AI to create synthetic data
Stanford Medicine describes RoentGen, an open model developed by researchers led by Curtis Langlotz and Akshay Chaudhari to generate realistic synthetic X-rays from medical descriptions. The stated target is data gaps in rare diseases and uncommon conditions where real imaging is limited. The piece frames synthetic X-rays as a way to reduce bias, improve privacy, and support more responsible imaging AI development.
- Imaging teams should treat text-to-image synthesis as a controllable “scenario generator” for coverage gaps, then measure whether downstream models generalize to real-world scans.
- Privacy leads still need clear boundaries: synthetic images can reduce exposure, but claims should be backed by formal privacy risk evaluation.
Longitudinal Synthetic Data Generation by Artificial Intelligence to Address Privacy, Fragmentation, and Data Scarcity
In the Journal of Clinical Cancer Informatics, researchers explore AI-generated longitudinal synthetic data aimed at privacy concerns, fragmented records, and scarcity in clinical research. The focus on longitudinal structure matters: many clinical questions depend on trajectories, not single snapshots. The work positions synthetic longitudinal data as a practical substrate for privacy-preserving ML when real patient timelines are hard to access or share.
- Longitudinal synthesis raises the bar on evaluation: teams must test whether temporal correlations and event sequences remain realistic enough for the intended analysis.
- For clinical partners, synthetic timelines can accelerate feasibility studies and pipeline development before negotiating access to identifiable data.